Oxaliplatin Dosing for Adult Cancer Patients with Impaired Renal Function
This study aims to determine the appropriate dosing of Oxaliplatin for adult cancer patients with impaired renal function, focusing on its safety and effectiveness in the treatment.
Oxaliplatin
Urogenital Diseases+13
+ Female Urogenital Diseases and Pregnancy Complications
+ Neoplasms by Site
Treatment Study
Summary
Study start date: September 1, 1999
Actual date on which the first participant was enrolled.Oxaliplatin is a diaminocyclohexane platinum derivative with known anticancer activity in solid tumors. The recommended single-agent dose of Oxaliplatin in adult cancer patients with normal renal function is 130 mg/m(2) given intravenously over 2 hours every 3 weeks. Renal excretion is thought to be the major route of drug elimination, but precise dosing guidelines in patients with abnormal renal function have not been determined. This phase I and pharmacologic study of single agent Oxaliplatin is being conducted in adult cancer patients with impaired renal function. Patients will be stratified into four groups based upon their degree of renal impairment as assessed by a 24 hour creatinine clearance. Group A will consist of 12 patients with normal renal function who will serve as pharmacologic controls. The remaining 3 groups will start at different doses of Oxaliplatin based upon their degree of renal dysfunction and dose escalation in these groups will proceed in a manner in accordance with standard phase I trials with 3 patients per dose level until dose limiting toxicity is observed. Pharmacokinetic monitoring will be performed in all patients on study. The goals of this trial are to define the toxicities and pharmacokinetics of single agent Oxaliplatin in this patient population and to determine recommended doses of Oxaliplatin in patient with different degrees of renal dysfunction.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.60 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Patients must have histologically confirmed malignancy which is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients with prior chemotherapy, radiation therapy, hormonal therapy and immunotherapy are allowed with the exception that patients cannot have had prior treatment with oxaliplatin. Patients greater than or equal to 18 years of age. Patients must have an ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60 percent) and a life expectancy of at least 3 months. Patients must have adequate organ and marrow function which includes: Leukocytes must be greater than or equal to 3,000/microliter. Absolute neutrophil count must be greater than or equal to 1,500/microliter. Platelet count must be greater than or equal to 100,000/microliter. Total bilirubin within normal institutional limits. AST (SGOT)/ALT(SGPT) less than or equal to 1.5 times the upper limit of normal. Patients with no evidence of clinically significant neuropathy. Women of child-bearing potential and men must agree to use adequate contraception. Patients must have the ability to understand and the willingness to sign a written informed consent document. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study, or within 6 weeks of prior platinum therapy will be excluded. Patients undergoing therapy with other investigational agents will be excluded. Patients with known brain metastaseswill be excluded. Patients with a history of an allergy to platinum compounds will be excluded. Patients with uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia will be excluded. Women must not be pregnant or nursing. Patients must not be HIV-positive or receiving anti-retroviral therapy (HAART). Patients actively receiving renal dialysis treatments while on the study will be excluded.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
National Cancer Institute (NCI)
Bethesda, United StatesOpen National Cancer Institute (NCI) in Google Maps